Celiac Disease and Portal Hypertension: A Causal Association or Just a Coincidence?

Tanwar, Amit Kumar; Gupta, Gaurav; Chauhan, Virender; Sharma, Deepak; Jain, Mukesh Kumar; Bhardwaj, Hemendra; Jhajharia, Ashok; Nijhawan, Sandeep

doi:10.1016/j.jceh.2019.11.005

Cited by 8 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seven studies including 1,876 patients with all-cause cirrhosis reported seroprevalence of CeD, and 235 were seropositive for 1 of the 3 serological tests namely anti-tTG2 Ab, AEA, and anti-DGP Ab; hence, the pooled seroprevalence of CeD was 14.2% (95% CI = 3.9%–28.8%; I 2 = 97%) (29,33,50,51,53–55) (Figure 3). Specific serology-based pooled seroprevalence estimates are summarized in Table 1.…”

Section: Resultsmentioning

confidence: 99%

“…Nine eligible studies including 497 patients with cryptogenic cirrhosis reported seroprevalence of CeD. Ninety patients among them were detected to be seropositive for one of the screening serological tests namely anti-tTG2 Ab, AEA, or anti-DGP Ab, suggesting an overall pooled seroprevalence of CeD of 15.3% (95% CI = 4.9%–29.5%, I 2 = 91%, P < 0.001) in patients with cryptogenic cirrhosis (7,28,29,33,34,46,50–52) (Figure 2).…”

Section: Resultsmentioning

confidence: 99%

“…Exploring the question of specific serology-based seroprevalence, the pooled seroprevalence based on anti-tTG2 Ab and AEA were 15.3% (95% CI = 4.9%–29.5%, n = 497 patients) (7,28,29,33,34,46,50–52) and 2.4% (95% CI = 0%–6.6%, n = 120 patients), respectively (28,29,52). Because no study had screened all patients in their sample for anti-DGP Ab, we could not estimate anti-DGP Ab–based seroprevalence (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…In all 9 studies reporting seroprevalence, 80% or more of the seropositive patients underwent mucosal biopsies. Among the 497 patients included in these studies, 31 patients had villous atrophy in the small intestinal biopsies in addition to being seropositive for CeD; hence, the pooled prevalence of biopsy-confirmed CeD in patients with cryptogenic cirrhosis was 4.6% (95% CI = 2.2%–7.5%, I 2 = 30%, P = 0.18) (7,28,29,33,34,46,50–52) (Figure 2). Age group–wise prevalence estimates are summarized in Table 1.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Prevalence of Celiac Disease in Patients With Liver Diseases: A Systematic Review and Meta-Analyses

et al. 2022

View full text Add to dashboard Cite

INTRODUCTION: A subset of patients with celiac disease (CeD) has liver involvement in the form of hypertransaminasemia, liver cirrhosis, and autoimmune hepatitis. We conducted a systematic review with meta-analyses to determine the pooled prevalence of CeD in patients with cryptogenic cirrhosis, all-cause cirrhosis, cryptogenic hypertransaminasemia, and all-cause hypertransaminasemia. METHODS:We searched PubMed and EMBASE up to January 2022. Cross-sectional, case-control, and prospective cohort studies performing serological tests and/or intestinal biopsy for CeD on patients with cryptogenic cirrhosis, all-cause cirrhosis, cryptogenic hypertransaminasemia, and all-cause hypertransaminasemia were included to calculate pooled estimates of seroprevalence and the prevalence of biopsy-confirmed CeD in these 4 groups. RESULTS:Of 6,871 articles screened, 20 articles were included finally in 3 meta-analyses for cryptogenic cirrhosis, all-cause cirrhosis, and cryptogenic hypertransaminasemia. For the all-cause hypertransaminasemia group, a qualitative review of 4 studies was conducted instead of a metaanalysis due to significant differences in studies. The pooled prevalence (95% confidence interval) of biopsy-confirmed CeD in cryptogenic cirrhosis was 4.6% (2.2%-7.5%) while the pooled prevalence of biopsy-confirmed CeD in all-cause cirrhosis was 0.8% (0%-3.4%). The pooled prevalence of biopsyconfirmed CeD in cryptogenic hypertransaminasemia was 5.7% (3.2%-8.8%).DISCUSSION:Nearly 1 in 20 patients each with cryptogenic cirrhosis and cryptogenic hypertransaminasemia have CeD; hence, they should both be considered high-risk groups for CeD. While the prevalence of CeD in those with all-cause cirrhosis is similar to that in general population, it may be worth screening them for CeD because liver pathology has the potential for reversal in them.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of Celiac Disease in Patients With Liver Diseases: A Systematic Review and Meta-Analyses

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A detailed flow of the studies included in the meta‐analysis is shown in figure 1 (PRISMA figure). The details of the included studies are shown in Table 1 17–67 . Excluded studies with reason of exclusion are shown in Table S2.…”

Section: Resultsmentioning

confidence: 99%

Liver abnormalities in celiac disease and response to gluten free diet: A systematic review and meta‐analysis

Jena

Kumar‐M

Kumar

et al. 2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim Liver involvement in celiac disease (CeD) is known but its various etiologies and the effect of gluten free diet (GFD) on it is understudied. Methods We searched PubMed, Medline and Embase databases from date of inception to March 7, 2022, to look for studies reporting on CeD and liver abnormalities. Pooled proportion of CeD patients with deranged transaminases, etiologies of various other liver diseases with CeD and the response to GFD were estimated. Subgroup analyses based on the age group, geographic distribution and duration of GFD were also carried out. Results Total 42 studies (8976 patients) reported hyper‐transaminasemia in patients with celiac disease. The pooled proportion of patients with elevated transaminases was 21.42% (95% CI: 17.02–26.59, I2 = 94%) overall, with similar prevalence among adults (21.20%) and children (21.51%). The commonest etiology was celiac hepatitis at 49.23% (95% CI: 30.09–68.59, I2 = 87%). Compliance with GFD was noted in 90.27%. The proportion of CeD patients with liver abnormalities who showed response to GFD was 86.39% (95% CI: 80.04–90.95, I2 = 74%) overall. Conclusion Liver involvement was noted in 21.42% of CeD patients. Celiac hepatitis was reported in nearly half of them. Good compliance and response were noted with GFD.

show abstract

Celiac disease: A rare cause of cirrhotic portal hypertension - A case report

Sawlani,

Masood,

Saahil

2024

Gastroenterology & Endoscopy

View full text Add to dashboard Cite

Celiac Disease and Portal Hypertension: A Causal Association or Just a Coincidence?

Cited by 8 publications

References 38 publications

Prevalence of Celiac Disease in Patients With Liver Diseases: A Systematic Review and Meta-Analyses

Prevalence of Celiac Disease in Patients With Liver Diseases: A Systematic Review and Meta-Analyses

Liver abnormalities in celiac disease and response to gluten free diet: A systematic review and meta‐analysis

Celiac disease: A rare cause of cirrhotic portal hypertension - A case report

Contact Info

Product

Resources

About